Skip to main content
Clinical Trials/NCT04886310
NCT04886310CompletedNot Applicable

Turkish Validity and Reliability Study of Peabody Developmental Motor Scale-2 in Infants Aged 0 - 24 Months

Ondokuz Mayıs University1 site in 1 country40 target enrollmentStarted: September 10, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
Peabody Developmental Motor Scale II (PDMS-2)

Study Overview

Brief Summary

This study is the determination of the Turkish version of the Peabody Developmental Motor Scale-2 and its Turkish validity reliability in infants age between 0 - 24 months and to spread its use for evaluation in early rehabilitation in our country.

Detailed Description

There are developments in the field of diagnosing children with a high risk of developmental disorders such as cerebral palsy (CP), mental problems and autism spectrum disorder in infancy . In particular, in infants experiencing the onset of extrauterine life in the neonatal intensive care unit, the combination of neonatal neuroimaging along with the assessment of general movements results in a highly accurate prediction of CP .A clinical tool often used in predictions is a neurological examination. Various standard variants are available, such as the Hammersmith Infant Neurological Examination (HINE), Alberta Infant Motor Scale (AIMS). PGMS-2 was developed by Folio and Fewell (2000) to determine the gross and fine motor development levels of children from birth to 71 months. The scale can be used for both children with healthy development and children with special needs. In the development of the Peabody Developmental Motor Scale (PGMS), which is the original version of PGMS-2 used in this study, a developmental structure was adopted instead of sticking to a certain theoretical perspective. PGMS is the first nationally standardized assessment tool that gives gross and fine motor scores separately in the United States of America (USA).This study is the determination of the Turkish version of the Peabody Developmental Motor Scale-2 and its Turkish validity reliability in infants age between 0 - 24 months and to spread its use for evaluation in early rehabilitation in our country.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
1 Month to 24 Months (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Infants between 0-24 months (adjusted age for premature infants will be calculated),who are followed as neurologically and developmentally at risk infants
  • Infants who are not in neonatal intensive care unit

Exclusion Criteria

  • Infants with congenital heart problems
  • Infants of families who do not accept the study
  • Infants with musculoskeletal system anomaly
  • Infants connected to respiratory equipment

Outcomes

Primary Outcomes

Peabody Developmental Motor Scale II (PDMS-2)

Time Frame: 45-60 minutes

is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.

Secondary Outcomes

  • The Alberta Infant Motor Scale (AIMS)(30-40 minutes)
  • Hammersmith Infant Neurological Examination (HINE)(30-45 minutes)

Investigators

Sponsor
Ondokuz Mayıs University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Nilay Comuk Balci

Pt, PhD, Associate Professor

Ondokuz Mayıs University

Study Sites (1)

Loading locations...

Similar Trials

Peabody Developmental Motor Scale-2 in 0 -... | Clinical Trial